Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2008
12/31/2008CN100446772C Treatment of diabetes
12/31/2008CN100446771C New medicinal composition
12/31/2008CN100446770C Water aerosol containing beclomethasone dipropionate
12/31/2008CN100446769C Medicine releasing composition for improving steroid compound stability
12/31/2008CN100446768C Mosapride citrate capsule and preparation process thereof
12/31/2008CN100446767C Use of GAL3 receptor antagonists for treatment of. depression and/or anxiety and compounds useful in such methods
12/31/2008CN100446766C Albendazole new form for treating nasal polyp and nasal polyp diseases
12/31/2008CN100446765C Albendazole new form for treating chronic rhinitis
12/31/2008CN100446764C Vitamic C controlled release pill and its preparation method and use
12/31/2008CN100446763C Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin
12/31/2008CN100446762C (-)-epigallocatechin gallate solid dispersion and its prepn and application
12/31/2008CN100446761C Application of scutellaria root extract in preparation of anti esophageal cancer medicine
12/31/2008CN100446760C Medicated chitin fiber for treating and preventing proliferation of mammary gland, prepn. method and application thereof
12/31/2008CN100446759C Gastrodine tablets disintegrating in oral cavity and process for producing same
12/31/2008CN100446757C Pharmaceutical compositions comprising atorvastatin manufactured without granulation
12/31/2008CN100446753C Clotrimazole gel, and its prepn. method
12/31/2008CN100446688C Method for preparing medicinal lining for preventing and treating mammary glands hyperplasia and application thereof
12/31/2008CN100446681C Fat-weight-reducing food
12/31/2008CN100446673C Kudzu root tea and its production method
12/31/2008CA2728386A1 Nasal and ophthalmic delivery of aqueous corticosteroid solutions
12/31/2008CA2704906A1 Food composition for prodromal dementia patients
12/31/2008CA2704282A1 Quinazolinone compounds and methods of use thereof
12/31/2008CA2699961A1 N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs
12/31/2008CA2696961A1 Treatment of heart failure in non-human animal mammals by an aldosterone antagonist
12/31/2008CA2694266A1 Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
12/31/2008CA2694238A1 Pharmaceutical aerosol compositions comprising fluticasone
12/31/2008CA2693226A1 New compounds with antithrombin function and pharmaceutical compositions on their basis
12/31/2008CA2692363A1 New anticoagulant compounds, pharmaceutical compositions comprising these compounds for treatment of thrombotic states, and plasma-substituting solutions to correct hypercoagulation defects of hemodilution
12/31/2008CA2692341A1 Use of a synergistic composition as a therapeutic agent or disinfectant
12/31/2008CA2692309A1 Improving memory in subjects with mini-mental state examination of 24-26
12/31/2008CA2692263A1 Immunocytokines for cancer treatment in combination with chemotherapeutic agents
12/31/2008CA2692221A1 Treatment of urinary tract infections with a mixture of saponin and an antibiotic
12/31/2008CA2692182A1 Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
12/31/2008CA2692155A1 Compositions comprising human egfr-sirna and methods of use
12/31/2008CA2692085A1 Fused thiazole derivatives as kinase inhibitors
12/31/2008CA2692021A1 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
12/31/2008CA2691956A1 Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
12/31/2008CA2691937A1 Substrate reduction therapy
12/31/2008CA2691932A1 Use of compounds for preparing anti-tuberculosis agents
12/31/2008CA2691888A1 New chemical compounds
12/31/2008CA2691849A1 Kallikrein 7 modulators
12/31/2008CA2691772A1 Crystalline polymorph of exemestane
12/31/2008CA2691597A1 Microspheres having core/shell structure
12/31/2008CA2691571A1 An inhalable composition
12/31/2008CA2691520A1 Composition for ophthalmic disease associated with hypoxia or ischemia
12/31/2008CA2691510A1 Compositions and methods of treating cancer
12/31/2008CA2691468A1 Methods and compositions for treating disorders
12/31/2008CA2691425A1 Compositions for the treatment of hyperphenylalaninemia
12/31/2008CA2691371A1 Duloxetine formulation
12/31/2008CA2691220A1 Remedy or preventive for integration dysfunction syndrome
12/31/2008CA2691215A1 Pyrazinone derivatives and their use in the treatment of lung diseases
12/31/2008CA2691200A1 Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
12/31/2008CA2691196A1 Methods of synthesizing cinacalcet and salts thereof
12/31/2008CA2691194A1 Polycyclic guanine derivatives and methods of use thereof
12/31/2008CA2691054A1 Combinations of sap depleting agents and anti-sap antibodies
12/31/2008CA2691010A1 Substituted fused pyrimidines as antagonists of gpr105 activity
12/31/2008CA2691005A1 Compositions comprising tryptophan hydroxylase inhibitors
12/31/2008CA2691003A1 Methods of treating serotonin-mediated diseases and disorders
12/31/2008CA2690975A1 Isoxazole-imidazole derivatives
12/31/2008CA2690847A1 Liquiritigenin and derivatives as selective estrogen receptor beta agonists
12/31/2008CA2690799A1 Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
12/31/2008CA2690782A1 Compositions and methods for treatment of cancer
12/31/2008CA2690737A1 6.5-pyrrolopiperidine tachykinin receptor antagonists
12/31/2008CA2690378A1 Phthalazine compounds, compositions and methods of use
12/31/2008CA2690344A1 Cysteine protease inhibitors
12/31/2008CA2690335A1 Benzazepine derivatives useful as vasopressin antagonists
12/31/2008CA2690294A1 Sildenafil n-oxide as prodrug
12/31/2008CA2690192A1 Imidazopyridinyl thiazolyl histone deacetylase inhibitors
12/31/2008CA2690191A1 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
12/31/2008CA2690145A1 Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
12/31/2008CA2690064A1 Benzimidazole amido derivatives as kinase inhibitors
12/31/2008CA2689945A1 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors
12/31/2008CA2689350A1 Treatment of depression
12/31/2008CA2689335A1 Use of estriol in low doses
12/31/2008CA2689330A1 Combination formulations
12/31/2008CA2689299A1 Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
12/31/2008CA2689109A1 N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
12/31/2008CA2689048A1 Formulations of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
12/31/2008CA2688494A1 Laser marked dosage forms
12/31/2008CA2687557A1 Polyfunctional fullerene c60 amino acid derivatives
12/31/2008CA2687165A1 Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension
12/31/2008CA2686225A1 Solubilized formulation of docetaxel without tween 80
12/31/2008CA2685072A1 Animal pest control method
12/30/2008US7470817 Acyclic and macrocyclic, aliphatic diammonium surfactants for use in forming lipid aggregates for drug delivery of macromolecules; improved versatility among different cell types and broadened range of molecules to be carried
12/30/2008US7470799 Dihydrobenzofuran derivatives and uses thereof
12/30/2008US7470798 7,8-bicycloalkyl-chroman derivatives
12/30/2008US7470797 Nuclear hormone receptor modulator; anticarcinogenic agent; 3-(4-Cyano-3-trifluoromethylphenylcarbamoyl containing 3-carboxy-14-dimethyl-5-oxa-7-oxybicyclo(2.2.2) heptane compound
12/30/2008US7470790 for treatment of various neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease; [6-(1-benzyl-4-hydroxy-pyrrolidin-3-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester
12/30/2008US7470776 Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
12/30/2008US7470724 Mycophenolic Acid having phosphonate groups attached either directly through a covalent bond or through a linking group; improved immunosuppressant activity and pharmacokinetic properties; Intracellular targeting for attaining high concentrations of phosphonate-containing molecules in target cells
12/30/2008US7470723 Diphenylethylene compounds and uses thereof
12/30/2008US7470722 For treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions
12/30/2008US7470720 Antiproliferative agents; synergistic mixture of anticarcinogenic agents with antiemetic
12/30/2008US7470719 Metastable benzoxepne derivatives which can be used in the treatment of dyslipidaemia a therosclerosis and diabetes, pharmaceutical compositions comprising them and processes for the preparation thereof
12/30/2008US7470718 Administering formulation selected from calcium-channel blocker; a combination of a calcium-channel blocker and glutamate inhibitor; a combination of a calcium-channel blocker and hypertensive agent or mixtures
12/30/2008US7470717 Indazole derivatives
12/30/2008US7470716 Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
12/30/2008US7470715 (+-)-4-{5-[1-(1-Hydroxy-ethyl)-cyclopropyl]-4-phenyl-isoxazol-3-yl}-phenol;new class of isoxazole derivative; breast cancer, migraine, incontinence, vaginal atrophy, bladder infection, senile gynecomastia, diabetes, hypoglycemia, melanoma, impotence, inflammatory bowel disease, CNS and GI disorders
12/30/2008US7470714 GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
12/30/2008US7470713 Imidazole based kinase inhibitors